Objectives: It is not known whether current use of the medication primidone affects brain γ-aminobutyric acid (GABA) concentrations. This is an important potential confound in studies of the pathophysiology of essential tremor (ET), one of the most common neurological diseases. We compared GABA concentrations in the dentate nucleus in 6 ET patients taking primidone versus 26 ET patients not taking primidone.
D espite its high prevalence, essential tremor (ET) is among the most poorly understood neurological diseases. On the most basic biological level, little is known about its underlying pathologic-anatomy and pathophysiology. 1 Several recent postmortem studies report a 30% to 40% reduction in Purkinje cells (PCs) in ET, suggesting that on a mechanistic level this common neurological disease could be neurodegenerative. [2] [3] [4] [5] [6] However, the presence and extent of PC loss in ET are the subject of considerable controversy 7 and therefore the focus of current scrutiny.
Purkinje cells are a major storehouse of brain γaminobutyric acid (GABA), releasing GABA into the synaptic cleft at the level of the cerebellar dentate nucleus. 8, 9 Thus, the cerebellar dentate GABA level could be a convenient in vivo marker of PC number. At present, we are conducting a longitudinal study that uses in vivo magnetic resonance spectroscopy (MRS) to quantify GABA concentrations in the cerebellar dentate nucleus. We expect that the proposed research, by testing the hypothesis that these concentrations will be low in ET patients compared with age-matched controls, will elucidate a critically important question about the underlying pathophysiology of ET. Aside from its scientific value, demonstrating low MRS-assessed GABA concentrations in ET could have an important clinical implication-MRS-assessed GABA concentration could serve as an imaging biomarker for ET. No such biomarkers currently exist.
Yet there is a complication. A potential contraindication for enrollment in this and other such studies is current exposure to medications that could influence brain GABAergic neurotransmission. By far, the most commonly used of these agents in ET is primidone, which is 1 of only 2 frontline medications used to treat ET. 10, 11 Studies estimate that approximately 50% of all ET patients have tried primidone. 12 Primidone is metabolized to phenobarbital, which binds to the GABA A receptor, potentiating GABAergic neurotransmission. 13 The question, which we now address, is whether current use of primidone affects dentate GABA concentrations. To our knowledge, this is unknown. The issue is an important one-if one were to exclude such treated ET patients, the potential loss of patients would be as much as 50%. In this cross-sectional study, we compared GABA concentrations in 2 cerebellar volumes of interest (VOIs; left and right), which included the dentate nucleus, comparing 6 ET patients taking daily primidone to 26 ET patients who were not taking primidone.
MATERIALS AND METHODS

Subjects and Clinical Evaluation
Essential tremor patients were recruited from several sources, including a clinical-epidemiological study of ET, 14 one of the author's (E.D.L.) neurological practices, and study advertisements. Inclusion criteria were (1) a prior diagnosis of ET assigned by a treating neurologist; (2) willingness to undergo a magnetic resonance imaging (MRI) scan as part of the current baseline study, as well as in a longitudinal study; and (3) living within 2 hours of the recruiting site. Exclusion criteria were (1) heavy exposure to ethanol (as defined previously), 15 (2) history of a neurodegenerative disease (Parkinson disease, Alzheimer disease), (3) prior deep brain stimulation or other neurosurgery (eg, γ-knife, thalamotomy) for ET, or (4) a reason to be excluded from MRI scanning (eg, metal in their bodies). Furthermore, we excluded most patients who were taking medications that bind to the GABA A receptor or that enhance GABA tone (eg, clonazepam, diazepam, gabapentin, phenobarbital, primidone, progabide, propofol, tigabine, valproate, vigabatrin); however, a small number of patients who were taking primidone were enrolled specifically for the purposes of the present analyses. In total, 106 ET patients were excluded for one of the aforementioned reasons.
Once enrolled, a trained research assistant conducted an inperson evaluation, administering demographic (eg, age, sex, race, education) and medical history questionnaires (eg, hand dominance, smoking history, tremor duration, number of drinks of ethanol per month). The Montreal Cognitive Assessment (MoCA) was performed as a brief assessment of cognitive function. 16 During the in-person assessment, a videotaped neurological examination was also performed. This included 1 test for postural tremor and 5 for kinetic tremor (12 tests total). A senior neurologist specializing in movement disorders (E.D.L.) used a reliable and valid clinical rating scale, the Washington Heights-Inwood Genetic Study of Essential Tremor rating scale, to rate postural and kinetic tremor during each test: 0 (none), 1 (mild), 2 (moderate), 3 (severe), resulting in a total tremor score (range, 0-36). 17 Diagnoses of ET were reconfirmed by E.D.L. using the videotaped neurological examination and the Washington Heights-Inwood Genetic Study of Essential Tremor diagnostic criteria (moderate or greater amplitude kinetic tremor [tremor rating ≥2] during ≥3 tests or a head tremor, in the absence of Parkinson disease, dystonia, or another cause). 18, 19 The study protocol was reviewed and approved by the Human Subjects Institutional Review Board at Yale University, Purdue University, and at Weill Cornell Medical College. Written informed consent was obtained from each subject prior to participation in the study.
In Vivo MRI/MRS Measurements
Magnetic resonance imaging and 1 H MRS examinations were performed on a 3.0-T Siemens Tim Trio scanner (Siemens Healthcare, Erlangen, Germany), equipped with a 32-channel head coil. All scans were performed at Weill Cornell Medical College. Fast T 2 -weighted images were acquired in all 3 orientations to ensure exact localization of the MRS VOIs. γ-Aminobutyric acid-edited MRS data were acquired from 2 VOIs containing the left and right cerebellar dentate nucleus, respectively (both 25 Â 25 Â 25 mm, 128 averages) ( Fig. 1 ). Both dentate nuclei were clearly identified on the T 2 -weighted images on both axial and coronal planes. Each GABA VOI was placed on the axial plane such that the entire dentate nucleus was included, given the fact that this is the level at which the PCs release their GABA into the synaptic cleft, 8 while minimizing contributions from vascular and cerebrospinal fluid (CSF) compartments. The VOI was then confirmed to be completely within the cerebellum on the coronal plane. The MEGA-PRESS J-editing sequence was used for GABA detection (repetition time/time to echo = 1500/68 milliseconds). 20 One hundred ninety-six averages were acquired with the spectrally selective editing pulse centered at 1.9 ppm (edit-on) and 196 averages with the pulse centered at 7.5 ppm (edit-off) in an interleaved fashion. The resulting difference spectrum contains a GABA peak at 3.0 ppm, which also includes contributions from coedited macromolecules and homocarnosine, a dipeptide consisting of GABA and histidine. Therefore, the signal will be referred to as GABA+. For both VOIs, a reference spectrum was acquired without water suppression. These reference spectra were then used for phase and frequency correction of the corresponding water-suppressed spectra. FASTESTMAP shimming (IPR#577; Siemens Healthcare) was performed before each voxel measurement to achieve water line widths of less than 20 Hz. 21 In order to determine voxel tissue composition, high-resolution MPRAGE images were acquired (repetition time/time to echo/inversion time = 2300/2.91/900 milliseconds, flip angle = 9 degrees, bandwidth 240 Hz/pixel, voxel size 1.0 Â 1.0 Â 1.2 mm, GRAPPA = 2). Every effort was made to ensure the subjects were as comfortable as possible in the scanner.
Data Processing and Analysis
Magnetic resonance spectroscopy data processing and quantification were performed with LCModel 6.3-0L, 22 fitting each spectrum as a weighted linear combination of basis spectra from individual metabolites. For fitting the MEGA-PRESS spectra, basis sets were generated from density matrix simulations of the sequence using published values for chemical shifts and J-couplings from Kaiser et al, 23 with an exact treatment of metabolite evolution during the 2 frequency-selective MEGA inversion pulses. LCModel fitting %SD values were lower than 20% for GABA+ in all spectra. γ-Aminobutyric acid-positive concentrations were derived from raw GABA+ output values from LCModel, multiplied with a water calibration factor provided by LCModel (FCALIB factor). Because of scaling uncertainties, GABA+ concentration values are given in institutional units but are proportional to and in the range of the true GABA+ concentrations in millimolars.
To determine and correct for the tissue composition of the MRS voxels, MPRAGE images were segmented into gray matter, white matter, and CSF using an in-house MATLAB 2013a (MathWorks Inc, Natick, Mass) code, incorporated with statistical parametric mapping (SPM8; Wellcome Department of Imaging Neuroscience, London, United Kingdom). γ-Aminobutyric acid levels corrected for CSF were obtained using the method described by Chowdhury et al. 24 
Sample Size Calculation
In order to calculate sample size, we used our won pilot MRS data on dentate GABA concentration in 5 ET patients who were not taking primidone. We determined that with 6 treated and 26 untreated patients, we would have 80% power to detect as little as a 25% difference in dentate GABA concentration between groups (assuming a 2-sided Student t test and α = 0.5). Given published data showing 50% to 70% increases in MRS-assessed brain GABA concentrations in animals and humans treated with GABAergic medications, [25] [26] [27] [28] this sample size was considered adequate.
Statistical Analyses
All analyses were performed in SPSS (version 21.0, Armonk, NY). We used Student t tests, Fisher exact tests, and Mann-Whitney U tests (for variables that were not normally distributed) to compare the demographic and clinical features of ET patients on primidone versus ET patients off primidone ( Table 1 ). We also assessed the correlations between dentate GABA concentration and demographic and clinical features using Student t tests as well as correlation coefficients (Pearson for normally distributed variables and Spearman for variables that were not normally distributed) ( Table 2 ). In linear regression models, we adjusted for potential confounds (ie, variables that were associated, even to a marginal degree, with primidone status or with dentate GABA concentration) in the association between primidone status (treated vs untreated) and dentate GABA concentrations (dependent variable).
RESULTS
The 2 groups were similar to one another in terms of age, sex, race, education, smoking status, hand dominance, total tremor score, and MoCA score ( Table 1 ). The mean tremor duration was nearly 10 years longer for the primidone group, although this difference did not reach statistical significance ( Table 1 ). The median number of drinks of ethanol was greater for the primidone group (21.5 vs 3.2), but this difference did not reach statistical significance either (Table 1) .
In our 32 patients, dentate GABA concentration was not correlated with age, sex, years of education, total tremor score, or median number of drinks of ethanol per month ( Table 2) . Higher right, but not left, dentate GABA concentration was weakly associated with lower MoCA score (r = −0.42, P = 0.03, Table 2 ). Higher left, but not right, dentate GABA concentration was marginally associated with longer tremor duration (r = 0.39, P = 0.06, Table 2 ).
Both, the right and left dentate GABA concentrations were similar in the 2 groups (right: 2.21 ± 0.46 [on primidone] vs 1.93 ± 0.39 [not on primidone], t = 1.49, P = 0.15; left: 1.61 ± 0.35 [on primidone] vs 1.67 ± 0.34 [not on primidone], t = 0.36, P = 0.72) (Fig. 2) .
In the 6 treated patients, the daily primidone dose ranged from 50 to 750 mg (mean, 312.5 [SD, 309.2] mg); there was no association between this dose and either right dentate GABA concentration (Pearson r = 0.11, P = 0.89) or left dentate GABA concentration (Pearson r = −0.24, P = 0.76).
In a linear regression model that adjusted for potential confounds (number of drinks of ethanol per month, tremor duration, MoCA score), taking primidone was not associated with the right dentate GABA concentration (β = 0.27, P = 0.17). Similarly, adjusting for the same potential confounds, taking primidone was not associated with the left dentate GABA concentration (β = −0.24, P = 0.22).
DISCUSSION
To our knowledge, this is the first study to examine the effects of current daily administration of primidone on MRSassessed dentate GABA concentration. The current data address a question about a major potential confound in studies of GABA in ET. Importantly, we did not find a difference in dentate GABA concentrations in 6 ET patients taking daily primidone compared with 26 ET patients who were not taking primidone. Furthermore, there was no association between daily primidone dose and dentate GABA concentration. r p = −0.006 r p = 0.10 P = 0.98 P = 0.61 Sex Male 1.91 ± 0.46 1.66 ± 0.36 Female 2.08 ± 0.33 1.65 ± 0.32 t = 1.12, P = 0.27 t = 0.05, P = 0.96 Education (y) r p = −0.16 r p = −0.002 P = 0.43 P = 0.99 Total tremor score r p = −0.17 r p = 0.11 P = 0.36 P = 0.60 Tremor duration (y) r p = −0.19 r p = 0.39 P = 0.34 P = 0.06 MoCA score r p = −0.42 r p = 0.16 P = 0.03 P = 0.45 Median no. of drinks of ethanol per month r s = 0.03 r s = 0.16 P = 0.86 P = 0.43
Values represent correlation coefficients (r p = Pearson and r s = Spearman) or mean ± SD.
The published literature has not directly addressed the issue we focus on in this study. Indeed, the small number of related published studies differ from ours in numerous respects and their results are mixed. These data will be reviewed in the paragraphs below, beginning with the human studies and then moving to the animal studies.
In an MRS study, 17 healthy adults were randomly assigned to receive one of the following medications with GABAergic properties: topiramate, gabapentin, or lamotrigine. γ-Aminobutyric acid was measured using a 4.1-T magnet from a 13.5-mL volume over the occipital region 3 and 6 hours following administration of an acute single dose and 2 and 4 weeks after dose titration. During the acute phase, GABA concentrations rose 70% (topiramate) and 48% (gabapentin), but not with lamotrigine. With long-term dosing, significant elevations in GABA were observed compared with baseline for all 3 drugs (topiramate 46%, gabapentin 25%, and lamotrigine 25%). 25 The study differed from ours in the sense that the patients were not ET patients, the medication of interest in our study (primidone) was not studied, and GABA concentrations in a VOI containing the dentate nucleus were not assessed.
In another study, the authors performed a single-dose 900-mg gabapentin challenge in healthy human subjects in order to explore its effects on GABA concentrations measured with 1 H-MRS in the visual cortex. Gabapentin administration was associated with an average increase in GABA concentration of 55.7% (range, 6.9%-91.0%). 26 That study differed from ours in multiple respects, including the specific medication used, the study population (ET vs controls), the chronicity of drug usage (single dose vs chronic use), and the location of the MRS voxel.
In another study, the effects of gabapentin and vigabatrin were assessed on GABA concentrations in human (n = 14) and rat (n = 6) neocortical slice preparations. Neocortical slices were incubated with gabapentin, vigabatrin, or no drugs for 3 hours. Proton MRS of perchloric acid extracts was used to measure GABA concentrations. Vigabatrin increased cellular GABA concentrations in both human and rat neocortical slices by 62% (P < 0.001) and 88% (P < 0.03), respectively. Gabapentin significantly increased GABA concentrations by 13% (P < 0.02) in human neocortical slices but not in rat neocortical slices. 27 In another study, the effects of gabapentin, pregabalin, and vigabatrin on brain MRS GABA concentrations were studied in Long-Evans rats. Two hours after intraperitoneal injection of 100 mg/kg gabapentin, no differences were observed in GABA concentrations in rats treated with gabapentin. For pregabalin, no effect was observed. Vigabatrin produced a 50% increase in GABA. The authors concluded that although gabapentin and pregabalin are anticonvulsants designed to mimic GABA, these drugs do not raise GABA levels acutely. 29 In an earlier study 28 of albino mice, the authors administered primidone and measured brain GABA levels in the cerebral hemispheres. This is the only study we are aware of that has focused on this medication (primidone), as did we. They found that primidone (50 mg/kg intraperitoneally) did not raise the brain GABA concentrations in these animals.
Overall, one can see that the results are mixed with respect to animal versus human data, with respect to the effects of specific GABAergic agents relative to one another, and with respect to the acute versus chronic effects of the same agents. The 1 study 28 that assessed primidone; however, found that intraperitoneally delivered primidone did not raise the brain GABA concentrations.
This study had a number of limitations. First, our VOI was large compared with the size of the dentate nucleus. This was necessary in order to obtain a GABA-edited spectrum with sufficient signal-to-noise ratio for adequate quantification. Thus, it is conceivable that our sensitivity to detect very small changes in dentate GABA may have been insufficient, especially if the GABA concentration of the surrounding cerebellar tissue, which was comeasured, did not change. Second, we did not precisely standardize when the 6 treated study subjects took their usual morning primidone dose. However, all 6 of them took their dose on the morning of the scan, and the latency between dose and scan ranged from 1 to 6 hours. As noted above, in a study 28 of albino mice, the authors noted that primidone administered intraperitoneally did not acutely raise brain GABA concentrations. Third, the number of study subjects taking primidone was small (n = 6). Despite this, we were powered to detect as little as a 25% difference between study groups. Given the available published data, which show 50% to 70% increases in MRS-assessed brain GABA concentrations in animals and humans treated with GABAergic medications, [25] [26] [27] [28] this sample size was considered more than adequate.
In summary, we did not find a difference in dentate GABA concentrations in 6 ET patients taking daily primidone compared with 26 ET patients who were not taking primidone. Furthermore, there was no association between daily primidone dose and dentate GABA concentration. These data suggest that it is not necessary to exclude ET patients on primidone from MRS studies of dentate GABA concentration and, if such concentrations were eventually to be developed as a biomarker for ET, that use of primidone would not confound the interpretation of the results.
